4887-95-0

Usage

Uses

Used in Organic Synthesis:
2,5-Dichlorobenzimidazole is used as a reagent in organic synthesis for its ability to facilitate specific chemical reactions, contributing to the formation of desired products in the synthesis process.
Used as an Intermediate in Chemical Production:
2,5-DICHLOROBENZIMIDAZOLE serves as an intermediate in the production of other chemicals, playing a crucial role in the synthesis of various compounds for different applications.
Used in Industrial Processes as a Corrosion Inhibitor:
2,5-Dichlorobenzimidazole is employed as a corrosion inhibitor to protect materials from degradation in industrial processes, thereby extending the service life of equipment and structures.
Used in Agriculture as a Fungicide:
In agricultural applications, 2,5-Dichlorobenzimidazole is used as a fungicide to control fungal infections in crops, helping to maintain plant health and productivity.

InChI:InChI=1/C7H4Cl2N2/c8-4-1-2-5-6(3-4)11-7(9)10-5/h1-3H,(H,10,11)

Upstream product

• 2034-23-3 5-chloro-1,3-dihydrobenzoimidazol-2-one 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 25369-78-2 5-chloro-1,3-dihydro-2H-benzo[d]imidazole-2-thione 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 40828-56-6 5(6)-Chlorobenzimidazole-2-sulfonic acid 

Downstream Products

• 1012331-88-2 C₂₅H₂₀Cl₂FN₅O 
• 24752-26-9 (5-chloro-1⁽³⁾H-benzoimidazol-2-yl)-(4-chloro-phenyl)-amine 
• 86601-38-9 (5-chloro-1⁽³⁾H-benzoimidazol-2-yl)-phenyl-amine 
• 1049798-98-2 5⁽⁶⁾-chloro-2-(3-chloro-4-fluoroanilino)-1H-benzimidazole hydrochloride 
• 1049799-17-8 5⁽⁶⁾-chloro-2-(4-trifluoromethylanilino)-1H-benzimidazole hydrochloride 
• 401567-04-2 3-{(2S,4S)-1-benzyloxycarbonyl-4-[4-(5-chlorobenzimidazol-2-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine 
• 1453097-56-7 C₂₂H₁₅ClN₄O 
• 1453097-15-8 1-(5-chloro-1H-benzimidazol-2-yl)-3-methyl-4-(phenylmethyl)-1H-pyrazol-5-ol 
• 99122-11-9 5-chloro-2-hydrazino-1H-benzimidazole 
• 1197337-91-9 C₁₆H₁₃ClN₄O 
• 1073558-72-1 8-(6-chloro-1H-benzimidazol-2-yl)-3-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one trifluoroacetate 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 5418-93-9 6-chloro-1H-benzoimidazol-2-amine 

Relevant academic research and scientific papers

Benzimidazole derivatives, their preparation and their application in medicine and pharmacology (by machine translation)

The invention relates to a new control or inhibit indocyanine 2, 3 - dioxygenase (IDO) activity of the benzimidazole derivatives, their preparation and their application in medicine and pharmacology. Specifically, the invention relates to a compound of general formula (I) compound of formula and its pharmaceutically acceptable salt, containing the compound or its pharmaceutically acceptable salt of the pharmaceutical composition, the use of the compound or its pharmaceutically acceptable salts for treating and/or preventing the relevance of the IDO-mediated disease, especially a tumor of the method and the compound or its pharmaceutically acceptable salts thereof. The invention also relates to the compound or its pharmaceutically acceptable salt or containing the compound or its pharmaceutically acceptable salts for the preparation of a pharmaceutical composition for treating and/or preventing the relevance of the IDO-mediated disease, in particular of the use of the drug in the tumor. Wherein the general formula (I) of each substituent is as defined in the specification. (by machine translation)

NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF

The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is a

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.

SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY

The invention provides PKA and PKB kinase-inhibiting compounds of the formula (I); or salts, solvates, tautomers or N-oxides thereof, wherein E is a five membered heteroaryl ring containing 1, 2, 3 or 4 heteroatoms selected from O, N and S provided that no more than 1 heteroatom may be other than N; q and r are each is 0 or 1; provided that q+r is 1 or 2; T is N or a group CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N- C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); Q3 is a bond or a saturated C1-3 hydrocarbon linker group optionally substituted by fluorine and hydroxy; G is NR2R3, CN or OH; m and n are each 0 or 1, provided that m+n is 1 or 2, and provided also that m or n are each 0 when the adjacent ring member of ring E is S or O; R1a and R1b are the same or different and each is hydrogen or a substituent R10; or R1a and R1b together with the carbon atoms or heteroatoms to which they are attached form a 5 or 6-membered aryl or heteroaryl ring, wherein the aryl or heteroaryl rings are optionally substituted by one or more substituents R10; and R2, R3, R4, R5, R7, R6, R8, and R10 are as defined in the claims.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists

A series of 4-(2-pyridyl)piperazine-1-benzimidazole analogues based on compound 1 was synthesized and evaluated for TRPV1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human TRPV1-expressing HEK293 cell line. Potent TRPV1 antagonists were identified through SAR studies. From these studies, several antagonists were found, with IC50 values ranging from 32 nM to ～5000 nM. Among these, 11 [IC50 = 90 nM (CAP) and 104 nM (pH)] was further evaluated and found to be orally available in rats (F% = 19.7).

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

PROLINE DERIVATIVES AND USE THEREOF AS DRUGS

The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.

An improved large-scale preparation of benzimidazole-2-sulfonic acids and 2-chlorobenzimidazoles

An improved method for the preparation of benzimidazole-2-sulfonic acids from 2-mercaptobenzimidazoles has been developed which utilizes aqueous sodium percarbonate. 2-chlorobenzimidazoles were obtained in high yield from the corresponding sulfonic acids upon reaction with PCl5 in POCl3 on a gram-mole scale.